This article is more than 5 years old. Information may no longer be current.
Consensus lacking on lupus management and other top dermatology stories
In an online survey, dermatologists and rheumatologists agreed on appropriate screening labs for discoid lupus erythematosus, but differences in disease-modifying risk factors exist, according to the most-read Healio Dermatology story last week.
In a study on rosacea, combination treatment of topical ivermectin 1% cream and oral doxycycline 40 mg provides a greater reduction in papulopustular lesions in as early as 4 weeks. Study researcher James Q. Del Rosso, DO, talked about the clinical impact of the study and the advantages to this treatment.
Survey: Rheumatologists, dermatologists lack consensus on lupus management
An online survey of dermatologists and rheumatologists managing patients with systemic lupus erythematosus revealed areas of consensus in laboratory studies and also some practice-based differences. Read more.
Combination therapy yields greater improvement in severe rosacea
Patients with rosacea treated with topical ivermectin 1% cream and oral doxycycline modified-release 40 mg capsules had greater visible improvement and decreased stinging and flushing compared with monotherapy, according to data from a multicenter, randomized, parallel-group comparison study. Read more.
Researchers propose use of ‘chronic pruritus of unknown origin’ designation
Researchers recommend new nomenclature of “chronic pruritus of unknown origin,” or CPUO, a diagnostic workup and classification to help increase the understanding of chronic pruritus. Read more.